Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug improve joint replacement outcomes?

NCT ID NCT07755085

Disease control Sponsor: Nova Scotia Health Authority Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether taking a GLP-1 medication (semaglutide) for at least six months before hip or knee replacement surgery can improve recovery and reduce complications in patients with obesity. Participants will be randomly assigned to receive either the medication plus behavioral support (diet, exercise, counseling) or a placebo with the same support. The study will track wound complications, weight loss, and mobility changes to see if this approach helps high-risk patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (a GLP-1 receptor agonist) combined with structured behavioral modification (diet, exercise, counseling)
What this could lead to
If effective, this approach could reduce surgical complications and improve recovery for obese patients undergoing joint replacement, potentially leading to better standard care.
What could go wrong
This is a small pilot study, so results may not be conclusive. The medication may not reduce complications and could have side effects, and the behavioral program adds complexity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon * Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+ * Patients must be between 18-90 years of age * Able to provide informed consent Exclusion Criteria: * Cognitive impairment that precludes study participation and compliance * Patients unwilling to undergo smoking cessation prior to surgery * Patients currently taking biologic medications that suppress the immune system * Patients currently taking GLP-1 medications * Patients with a contraindication to GLP-1 medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arthritic joint disease Obesity obesity disorder osteoarthritis, hip osteoarthritis, knee Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis GLP - 1 Obesity / overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nova Scotia Health

    Dartmouth, Nova Scotia, B2Y 2N5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.